STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.
The gastrointestinal stromal tumor cell line, GIST-T1, has a heterogenic 57-base pair deletion in exon 11 of the c-kit mutation, and the c-KIT protein in the GIST-T1 cells constitutively activated. We report that STI571 (Glivec; Novartis, Basel, Switzerland), a specific inhibitor of c-KIT, inhibits the clustering of c-KIT at the cell membrane of the GIST-T1 cells. Furthermore, STI571 prevents the interaction between c-KIT and the molecular chaperone, heat shock protein 90 (Hsp90). Geldanamycin, an inhibitor of Hsp90, also prevents interaction between c-KIT and Hsp90, and inhibits tyrosine phosphorylation of c-KIT. Our results indicate that c-KIT molecules are assembled on the cell surface of the GIST-T1 cells, and that the interaction between c-KIT and Hsp90 plays an important role in c-KIT activation.
Nakatani
Hajime
H
Department of Tumor Surgery, Kochi Medical School, Nankoku, Kochi, 783-8505, Japan. nakatanh@kochi-ms.ac.jp
Kobayashi
Michiya
M
Jin
Toufeng
T
Taguchi
Takahiro
T
Sugimoto
Takeki
T
Nakano
Takumi
T
Hamada
Shinichi
S
Araki
Keijiro
K
D001549:Benzamides; D016227:Benzoquinones; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D004347:Drug Interactions; D046152:Gastrointestinal Stromal Tumors; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D047029:Lactams, Macrocyclic; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology*; D011809:Quinones / Q000494:pharmacology
D001549:Benzamides; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D010879:Piperazines; D011743:Pyrimidines; D011809:Quinones; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; C001277:geldanamycin
Science. 1998 Jan 23;279(5350):577-80
9438854
Lab Invest. 2002 May;82(5):663-5
12004007
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41
8962087
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14
9990072
Nature. 1995 Jan 26;373(6512):347-9
7530333
Oncogene. 1995 Dec 7;11(11):2419-27
8570194
Trends Mol Med. 2002;8(4 Suppl):S55-61
11927289
Am J Pathol. 1999 Jun;154(6):1643-7
10362788
Blood. 2000 Jan 15;95(2):726-7
10660321
EMBO J. 2000 Nov 1;19(21):5930-40
11060043
EMBO J. 1998 Dec 1;17(23):6879-87
9843494
J Biol Chem. 1997 Sep 19;272(38):23843-50
9295332
Cancer Sci. 2003 Apr;94(4):315-20
12824897
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
Histol Histopathol. 2000 Oct;15(4):1293-301
11005253
Cancer Res. 2001 Mar 1;61(5):2200-6
11280787
J Med Chem. 1999 Jan 28;42(2):260-6
9925731
Blood. 1999 Sep 15;94(6):1979-86
10477727
Adv Immunol. 1994;55:1-96
7508174